Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium

C.M. Zwaan, C Rizzari, F Mechinaud, DL Lancaster, T Lehrnbecher, Vincent van der Velden, BB Beverloo, Monique den Boer, Rob Pieters, D Reinhardt, M Dworzak, J Rosenberg, G Manos, S Agrawal, L Strauss, A Baruchel, PR Kearns

Research output: Contribution to journalArticleAcademicpeer-review


Purpose Dasatinib is a potent BCR-ABL inhibitor with proven efficacy in adults with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP) and in imatinib-resistant/intolerant disease. This phase I study of the Innovative Therapies for Children with Cancer Consortium assessed dasatinib safety and efficacy in pediatric patients. Patients and Methods Escalating once-daily dasatinib doses (60 to 120 mg/m(2)) were administered to children (n = 58) with (i) imatinib-pretreated CML or Philadelphia chromosome (Ph)-positive acute lymhoblastic leukemia (ALL) and (ii) treatment-refractory Ph-negative ALL or acute myeloid leukemia (AML). Results Dasatinib safety and efficacy profiles compared favorably with those in adults. The most common drug-related nonhematologic adverse events were nausea (31%, all grades; 2%, grade 3 to 4), headache (22%, 3%), diarrhea (21%, 0%), and vomiting (17%, 2%). Of 17 patients with CML-CP, 14 (82%) achieved complete cytogenetic response (CCyR) and eight (47%) achieved major molecular response. After 24 months of follow-up, median complete hematologic response (CHR) and major cytogenetic response (M Conclusion Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias.
Original languageUndefined/Unknown
Pages (from-to)2460-+
JournalJournal of Clinical Oncology
Issue number19
Publication statusPublished - 2013

Cite this